Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Amal M. Johnson Sells 4,635 Shares of Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Amal M. Johnson sold 4,635 shares of the business’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the transaction, the director now directly owns 12,275 shares in the company, valued at approximately $6,955,015. This represents a 27.41 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Intuitive Surgical Stock Performance

Shares of ISRG stock opened at $574.14 on Wednesday. Intuitive Surgical, Inc. has a 52-week low of $364.17 and a 52-week high of $616.00. The business’s fifty day moving average is $548.00 and its 200 day moving average is $506.12. The company has a market capitalization of $204.50 billion, a PE ratio of 92.31, a price-to-earnings-growth ratio of 5.19 and a beta of 1.39.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Oppenheimer reissued a “market perform” rating on shares of Intuitive Surgical in a report on Friday, October 18th. Piper Sandler reissued an “overweight” rating and set a $670.00 target price (up from $538.00) on shares of Intuitive Surgical in a research report on Friday, January 24th. Morgan Stanley upgraded shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $522.00 to $650.00 in a research note on Monday, December 2nd. Raymond James upped their price objective on Intuitive Surgical from $560.00 to $688.00 and gave the company an “outperform” rating in a research note on Friday, January 24th. Finally, Truist Financial raised their target price on Intuitive Surgical from $640.00 to $666.00 and gave the stock a “buy” rating in a research report on Friday, January 24th. One analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $613.10.

Institutional Trading of Intuitive Surgical

Several institutional investors and hedge funds have recently modified their holdings of the business. Bennett Selby Investments LP increased its position in shares of Intuitive Surgical by 3.9% in the fourth quarter. Bennett Selby Investments LP now owns 449 shares of the medical equipment provider’s stock worth $234,000 after purchasing an additional 17 shares during the last quarter. LVW Advisors LLC raised its stake in shares of Intuitive Surgical by 1.3% during the fourth quarter. LVW Advisors LLC now owns 1,448 shares of the medical equipment provider’s stock worth $756,000 after acquiring an additional 19 shares in the last quarter. Wesbanco Bank Inc. lifted its holdings in shares of Intuitive Surgical by 1.6% in the 4th quarter. Wesbanco Bank Inc. now owns 1,216 shares of the medical equipment provider’s stock worth $635,000 after acquiring an additional 19 shares during the last quarter. FSM Wealth Advisors LLC boosted its stake in shares of Intuitive Surgical by 3.7% in the 4th quarter. FSM Wealth Advisors LLC now owns 526 shares of the medical equipment provider’s stock valued at $275,000 after purchasing an additional 19 shares in the last quarter. Finally, Journey Strategic Wealth LLC grew its holdings in shares of Intuitive Surgical by 1.9% during the 4th quarter. Journey Strategic Wealth LLC now owns 1,039 shares of the medical equipment provider’s stock valued at $542,000 after purchasing an additional 19 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.